Investigator-driven randomised controlled trial of cefiderocol vs standard therapy for healthcare associated and hospital acquired Gram-negative bloodstream infection (GAMECHANGER)

Background : Cefiderocol has in vitro activity against multi-drug resistant (MDR) and extensively-drug resistant (XDR) gram-negative bacilli. It is FDA- and EMA-approved, but efficacy in bloodstream infections (BSI) is uncertain. We undertook a multicentre, open label, randomised trial comparing cef...

Full description

Bibliographic Details

Main Authors:	Paterson, D. L., Sulaiman, H., Po-Yu, L., Chatfield, M., Yilmaz, M., Salmuna, Z. N., Mazlan, M. Z., Anunnatsiri, S., Sirijatuphat, R., Chotiprasitsakul, D., Lye, D., Somani, J., Kalimuddin, S., Thamlikitkul, V., Lee, Y. T., Lin, Y. T., Yang, Y. S., Wan Ramli, Wan Nurliyana, Ong, H. C., Mootsikapun, P., Meesing, A., Tseng, C. H., Yeh, T. K., Hashim, A. M. B., Puangpatra, P., Aslan, A. T., Santanirand, P., Chiang, T. T., Archuleta, S., Chan, Y. F. Z., Chia, P. Y., Sahin, M., Yigitbasi, A. A., Forde, B., Wright, H., Stewart, A., Ling, W. P., Rossi, V., Harris-Brown, T., Harris, P. N. A.
Format:	Article
Language:	en
Published:	Elsevier 2024
Subjects:	RC111 Infectious and Parasitic Diseases
Online Access:	http://irep.iium.edu.my/120697/1/120697_Investigator-driven%20randomised.pdf http://irep.iium.edu.my/120697/ https://www.sciencedirect.com/science/article/pii/S2950590924000131?via%3Dihub
Tags:	Add Tag No Tags, Be the first to tag this record!